Publications

• INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
  Spach, D. H., Panther, L. A., Thorning, D. R., Dunn, J. E., Plorde, J. J., & MILLER, R. A. (1992). INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS. ANNALS OF INTERNAL MEDICINE, 116(9), 740–742.
• Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts
  Pershing, S., Dunn, J., Khan, A., & Liao, Y. J. (2009). Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts. JOURNAL OF NEURO-OPHTHALMOLOGY, 29(3), 223–226.
• Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
  Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., … Rose, J. W. (2010). Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. LANCET NEUROLOGY, 9(4), 381–390.
• Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis Dunn, J. (2010). Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 10(4), 433–440.
  
• Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis Dunn, J., & Blight, A. (2011). Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. CURRENT MEDICAL RESEARCH AND OPINION, 27(7), 1415–1423.
  
• Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein Herges, K., de Jong, B. A., Kolkowitz, I., Dunn, C., Mandelbaum, G., Ko, R. M., … Axtell, R. C. (2012). Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. MULTIPLE SCLEROSIS JOURNAL, 18(4), 398–408.
  
• Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis. (2005). ECTRIMS/ACTRIMS, (September).
  
• Comprehensive Outpatient Management of Patients with Multiple Sclerosis Comprehensive Outpatient Management of Patients with Multiple Sclerosis. (2001). RIMS MS Symposium, (May).
  
• Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV. (1992). Annals of Internal Medicine, 116.
  
• Atherosclerotic Aortic Disease as a Source of Embolic Infarct Atherosclerotic Aortic Disease as a Source of Embolic Infarct. (1996). Journal of Neurovascular Disease, 1(2).
  
• Gingko Biloba in the Treatment of Alzheimer's Disease Gingko Biloba in the Treatment of Alzheimer's Disease. (1998). Alternative Medicine, 1(15).
  
• Clinical Advisory Committee Statement Clinical Advisory Committee Statement. (1999). Health Care Connection, I(1).
  
• Novantrone in the Treatment of Multiple Sclerosis Novantrone in the Treatment of Multiple Sclerosis. (2001). Alliance News.
  
• Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis. (2008). Multiple Sclerosis, Apr 18.
  
• Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS. (2008). J Neurol, 255.
  
• Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS. (2007). Neurology, 68(12).
  
• Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II. (2007). ECTRIMS, 10/11/07.
  
• Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS. (2008). Multiple Sclerosis, 14.
  
• CMV Optic Neuritis with Extensive Tracking along the Visual Pathway CMV Optic Neuritis with Extensive Tracking along the Visual Pathway. (2009). J Neuro-Ophthalmology, 29(3).
  
• Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis. (2011). Current Research Medical Opinion, 27(7).
  
• The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. (2010). Expert Rev. Pharmacoeconomics Outcomes Res., 10(4).
  
• Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein. (2012). Multiple Sclerosis, 18(4).
  
• Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis. (2013). Annals of Neurology, 73(3).
  
• IFN-ß Treatment Requires B Cells for Efficacy in Neuroautoimmunity. Schubert, R. D., Hu, Y., Kumar, G., Szeto, S., Abraham, P., Winderl, J., … Axtell, R. C. (2015). IFN-ß Treatment Requires B Cells for Efficacy in Neuroautoimmunity. Journal of Immunology , 194(5), 2110–2116.
  
• Disease modifying therapies for non relapsing Multiple Sclerosis Dunn, J. (2013). Disease modifying therapies for non relapsing Multiple Sclerosis. Neurol Clin Pract, December(3).
  
• Mobility Concerns in Multiple Sclerosis Lee, J.-mi, & Dunn, J. (2013). Mobility Concerns in Multiple Sclerosis. US Neurology, 9(1).
  
• Alemtuzumab for patients with relapsing Multiple Sclerosis after disease modifying therapy: a randomized controlled Phase 3 trial. A, C. J., & CARE MS II, I. (2012). Alemtuzumab for patients with relapsing Multiple Sclerosis after disease modifying therapy: a randomized controlled Phase 3 trial. Lancet, Nov 24(380).
  
• Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Giovannoni, G., Cohen, J. A., Coles, A. J., Hartung, H.-P. P., Havrdova, E., Selmaj, K. W., … Compston, D. A. (2016). Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 87(19), 1985–1992.
  
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., … Compston, D. A. S. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. LANCET, 380(9856), 1829–1839.
  
• Ocrelizumab versus Interferon beta 1a in Relapsing Multiple Sclerosis Hauser, S. L., & OPERA Clinical Investigators. (2017). Ocrelizumab versus Interferon beta 1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 376(3).